A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours

BACKGROUND: Preclinical findings suggest that imatinib mesylate (IM) and metronomic cyclophosphamide (MC) combination provides synergistic antiangiogenic activity on both pericytes and endothelial cells. METHODS: We have designed a 3+3 dose-escalating phase I trial with a fixed dose of MC (50 mg two...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Adenis, A, Ray-Coquard, I, Italiano, A, Chauzit, E, Bui-Nguyen, B, Blay, J-Y, Tresch-Bruneel, E, Fournier, C, Clisant, S, Amela, E Y, Cassier, P A, Molimard, M, Penel, N
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2013
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3833229/
https://ncbi.nlm.nih.gov/pubmed/24149182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.648
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars